Sanofi Faces Scrutiny For Potential Multiple Sclerosis Blockbuster At Critical EMA Meeting

 
• By Francesca Bruce
  
Sanofi was this week scheduled to defend its MS drug at an EMA oral explanation meeting. (Shutterstock)

More from EMA

More from Agency Leadership